Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Telmisartan 80mg Non-responder Trial

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01222520
First received: October 15, 2010
Last updated: June 17, 2014
Last verified: January 2014

October 15, 2010
June 17, 2014
October 2010
June 2011   (final data collection date for primary outcome measure)
Reduction From the Reference Baseline in Mean Seated Diastolic Blood Pressure (DBP) at Trough [ Time Frame: Baseline, 8 weeks ] [ Designated as safety issue: No ]
Reference baseline: Status of patients after the 8-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing
The primary endpoint is the reduction from the reference baseline in mean seated DBP at trough (24-hour post-dosing) after 8 weeks of the double-blind treatment. [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01222520 on ClinicalTrials.gov Archive Site
  • Reduction From the Reference Baseline in Mean Seated Systolic Blood Pressure (SBP) at Trough [ Time Frame: Baseline, 8 weeks ] [ Designated as safety issue: No ]
    Reference baseline: Status of patients after the 8-week open-label run-in period with telmisartan monotherapy, where patients' eligibility to enter the double-blind treatment period was examined At trough: 24-hour post-dosing
  • Seated DBP Control Rate at Trough [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    DBP control rate: The rate of patients with controlled seated DBP at trough of less than 90 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing
  • Seated SBP Control Rate at Trough [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    SBP control rate: The rate of patients with controlled seated SBP at trough of less than 140 mmHg after the 8-week double-blind period At trough: 24-hour post-dosing
  • Seated DBP Response Rate at Trough [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    DBP response rate: The rate of patients who achieved an adequate response in seated DBP at trough (<90 mmHg and/or reduction from reference baseline ≥10 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing
  • Seated SBP Response Rate at Trough [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    SBP response rate: The rate of patients who achieved an adequate response in seated SBP at trough (<140 mmHg and/or reduction from reference baseline ≥20 mmHg) after the 8-week double-blind period At trough: 24-hour post-dosing
  • Seated Blood Pressure (BP) Normalisation at Trough [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
    Seated blood pressure (BP) normalisation: The numbers of patients whose blood pressure was within normalisation criterion in terms of seated blood pressure after the 8-week double-blind period At trough: 24-hour post-dosing
  • Reduction from the reference baseline in mean seated SBP at trough (24-hour post-dosing) after 8 weeks of the double-blind treatment [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Seated DBP control rate at trough after 8 weeks of the double-blind treatment [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Seated SBP control rate at trough after 8 weeks of the double-blind treatment [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Seated DBP response rate at trough after 8 weeks of the double-blind treatment from the reference baseline [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Seated SBP response rate at trough after 8 weeks of the double-blind treatment from the reference baseline [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Seated BP normalisation at trough after 8 weeks of the double-blind treatment [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Telmisartan 80mg Non-responder Trial
An Eight-week Randomised Double-blind Study to Compare the Efficacy and Safety of Telmisartan 80 mg+ Amlodipine 5 mg Fixed-dose Combination vs. Telmisartan 80 mg Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With Telmisartan 80 mg Monotherapy

If a patient cannot have his or her blood pressure controlled with telmisartan 80 mg, an antihypertensive drug from different class should be started concomitantly.

In the Japanese 3x3 factorial trial of telmisartan and hydrochlorothiazide in essential hypertension patients whose diastolic blood pressure (DBP) are equal or more than 95 mmHg, the DBP control rate (less than 90 mmHg) after 8 weeks treatment of the telmisartan 80 mg monotherapy group (66 patients) was 41.5%. There should be medical needs of the telmisartan 80 mg and amlodipine 5 mg fixed dose combination because some patients cannot have his or her blood pressure controlled with telmisartan 80 mg.

Thus, this clinical trial is being conducted to evaluate the antihypertensive effect and safety of a fixed-dose combination (FDC) drug of 2 antihypertensive agents with different pharmacological effects, telmisartan 80 mg and amlodipine 5 mg (T80/A5 mg), compared with telmisartan 80 mg (T80 mg) monotherapy in Japanese patients with essential hypertension who fail to respond adequately to treatment with the maximum dose of telmisartan 80 mg monotherapy. In this trial, a multi-centre, randomised, double-blind, double-dummy, active-controlled, parallel group comparison method is employed.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Hypertension
  • Drug: Telmisartan and amlodipine
    Telmisartan 80 mg and amlodipine 5 mg once a daily
  • Drug: Telmisartan
    80 mg once a daily
  • Experimental: Telmisartan and amlodipine FDC
    once a daily
    Intervention: Drug: Telmisartan and amlodipine
  • Active Comparator: Telmisartan monotherapy
    once a daily
    Intervention: Drug: Telmisartan
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
174
Not Provided
June 2011   (final data collection date for primary outcome measure)

Inclusion criteria:

  • Essential hypertensive patients

    • If already taking antihypertensive drugs, mean seated diastolic blood pressure (DBP) must be >=90 and >=114 mmHg
    • If not taking any antihypertensive drugs, mean seated DBP must be >=95 and >=114 mmHg
  • Able to stop all current antihypertensive drugs without risk to the patient based on the investigators opinion.

Exclusion criteria:

  • Patients taking 3 or more antihypertensive drugs at signing the informed consent form
  • Patients with known or suspected secondary hypertension
  • Patients with clinically relevant cardiac arrhythmia
  • Congestive heart failure with New York Heart Association (NYHA) functional class III-IV
  • Patients with recent cardiovascular events
  • Patients with a history of stroke or transient ischaemic attack within last 6 months before signing the informed consent form
  • Patients with a history of sudden deterioration of renal function with angiotensin II receptor blockers (ARBs) or angiotensin converting enzyme (ACE) inhibitors; or patients with post-renal transplant or post-nephrectomy
  • Patients who have previously experienced characteristic symptoms of angioedema (such as facial, tongue, pharyngeal, or laryngeal swelling with dyspnea) during treatment with ARBs or ACE inhibitors
  • Patients with known hypersensitivity to any component of the investigational product, or a known hypersensitivity to dihydropyridine-derived drugs
  • Patients with hepatic and/or renal dysfunction
  • Pre-menopausal women who are nursing or pregnant
Both
20 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
NCT01222520
1235.36
Not Provided
Boehringer Ingelheim
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Boehringer Ingelheim
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP